| Company Name: |
Daicel Chiral Technologies (China)CO.,LTD
|
| Tel: |
021-50460086-9 15921403865 |
| Email: |
han_yajun@dctc.daicel.com |
| Products Intro: |
Product Name:Duloxetine.HCl-D3
CAS:1188266-11-6
Purity:95%HPLC Package:10MG;25MG;50MG;100MG Remarks:DCTI-A-169
|
| Company Name: |
ChemStrong Scientific Co.,Ltd
|
| Tel: |
0755-0755-66853366 13670046396 |
| Email: |
sales@chem-strong.com |
| Products Intro: |
Product Name:rac-Duloxetine-d3 HCl
CAS:1188266-11-6
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Artis Biotech Co. Ltd.
|
| Tel: |
19138486554 18108108965 |
| Email: |
sales@artisbio.com |
| Products Intro: |
Product Name:Duloxetine D3 HCl/(±)-Duloxetine hydrochloride D3
CAS:1188266-11-6
Purity:99% HPLC Package:1mg 5mg 10mg 50mg 100mg
|
Duloxetine-d3 hydrochloride manufacturers
- Duloxetine-d3 HCl
-
- $457.00 / 1mg
-
2025-04-28
- CAS:1188266-11-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Duloxetine-d3 hydrochloride Basic information |
| Product Name: | Duloxetine-d3 hydrochloride | | Synonyms: | Duloxetine-d3 hydrochloride;rac-Duloxetine-d3 HCl;rac-Duloxetine-d3 Hydrochloride;N-(methyl-d3)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine,monohydrochloride;2H3]-Duloxetine HCl;Duloxetine D3 HCl/(±)-Duloxetine hydrochloride D3 | | CAS: | 1188266-11-6 | | MF: | C18H20ClNOS | | MW: | 333.87 | | EINECS: | | | Product Categories: | | | Mol File: | 1188266-11-6.mol |  |
| | Duloxetine-d3 hydrochloride Chemical Properties |
| storage temp. | Store at 4°C | | solubility | Water: 5 mg/ml | | form | A solid | | Water Solubility | Water: 5 mg/ml |
| | Duloxetine-d3 hydrochloride Usage And Synthesis |
| Description | Duloxetine-d3 is intended for use as an internal standard for the quantification of duloxetine by GC- or LC-MS. (S)-Duloxetine is a potent inhibitor of serotonin and norepinephrine reuptake (Kis = 4.6 and 15.6 nM, respectively, for rat synaptosomes). It also inhibits dopamine reuptake (Ki = 369 nM). (S)-Duloxetine suppresses spontaneous firing activity in vivo in the dorsal raphe and locus coeruleus (ED50s = 99 and 475 μg/kg, respectively). It also decreases immobility time and increases latency to first immobility in the forced swim test in mice when administered at doses of 16 and 32 mg/kg. Formulations containing (S)-duloxetine have been used in the treatment of major depressive disorder, generalized anxiety disorder, chronic neuropathic and musculoskeletal pain, and fibromyalgia. |
| | Duloxetine-d3 hydrochloride Preparation Products And Raw materials |
|